Paclitaxel, Carboplatin Plus Bevacizumab in Pretreated, Advanced or Metastatic Non Small Cell Lung Cancer

Exclusion Criteria

• •Previous therapy with paclitaxel in combination with carboplatin
• •Second primary malignancy, except for non-melanoma skin cancer and in situ cervical cancer
• •Pregnant or lactating women
• •Any serious, uncontrolled comorbidity on the investigator's judgment
• •Uncontrolled infection
• •Any sustained chronic toxicity \> grade 2 according to the NCI CTCAE (version 3.0)
• •Symptomatic neuropathy \> grade 2 according to the NCI CTCAE (version 3.0)
• •Brain metastases, except if radiated and asymptomatic
• •Radiotherapy within the previous 4 weeks
• •Previous radiotherapy to the only measurable lesion
• •Proteinuria ≥ 500 mgr of protein daily
• •Hemoptysis \> 10 cc per event
• •Clinically significant hematemesis
• •Centrally located lesion or in contact with major vessels
• •Pulmonary lesion with cavitation
• •Documented hemorrhagic diathesis or coagulation disorder
• •Cardiovascular disease (class II-IV NYHA congestive heart failure, myocardial infarction within the previous 4 months, unstable angina, LVEF \< normal, ventricular arrhythmia, uncontrolled hypertension)
• •Thrombotic event within the previous 6 months
• •Concurrent use of aspirin \> 325 mgr daily, low molecular weight heparin in therapeutic dose, warfarin or acenocoumarol, non-steroid anti-inflammatory agents
• •Concurrent treatment with other anti-cancer drug
• •Major surgical procedure within the previous 4 weeks